Targeting the Microenvironment to Overcome Gemcitabine Resistance in Pancreatic Cancer.
Cancer Res
; 80(15): 3070-3071, 2020 08 01.
Article
em En
| MEDLINE
| ID: mdl-32753486
ABSTRACT
Pancreatic cancer is characterized by an extensive and complex microenvironment, and is resistant to both chemotherapy and immune checkpoint blockade. The study by Principe and colleagues in this issue of Cancer Research proposes a combinatorial approach based on targeting the very mechanisms of resistance to gemcitabine, a commonly used chemotherapeutic agent. The authors show that gemcitabine treatment causes profound changes in the pancreatic cancer microenvironment, including elevated TGFß signaling and immune checkpoint expression, as well as increased antigen presentation in tumor cells. Accordingly, they show that the combination of chemotherapy, TGFß signaling inhibition, and immune checkpoint blockade effectively restores antitumor immunity and results in a significant survival benefit.See related article by Principe et al., p. 3101.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Pancreáticas
/
Carcinoma
Limite:
Animals
Idioma:
En
Revista:
Cancer Res
Ano de publicação:
2020
Tipo de documento:
Article